Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
US5861510A · kind A · utility
199Cited by
5References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 7, 1997 |
| Grant date | Jan 19, 1999 |
| Priority date | — |
| Expiry date | Oct 7, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D241/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound of the formula ##STR1## wherein R.sup.1, R.sup.2 R.sup.3, R.sup.4 R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9 and Ar are as defined above, useful in the treatment of a condition seiected from the group consisting of arthritis, cancer, tisuue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other disease characterized by matrix metalloproteinase activity, as well as AIDS, sepsis, septic shock and other diseases involving the production of TNF.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.